GlassScriptPhysician profile
Howard S Yeh
NPI 1366698912
$26,360.58
in general payments reported to CMS, 2019-2025
76 companies · $5,295 in 2025
The $5,295 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $650 · 2021: $350 · 2022: $5,071 · 2023: $5,772 · 2024: $9,224 · 2025: $5,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $1,900 · Education: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,730.05 |
| Consulting Fee | $1,900.00 |
| Education | $659.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,878.17 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $1,968.89 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Genzyme Corporation | $1,374.80 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $1,249.69 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $1,234.83 | 2022-2025 | Vanflyta, Enhertu |
| Pfizer INC. | $1,124.69 | 2022-2025 | |
| Incyte Corporation | $1,122.79 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $1,113.61 | 2022-2025 | |
| Sobi, INC | $1,085.04 | 2022-2025 | |
| Astellas Pharma US INC | $969.66 | 2022-2025 | Vyloy, Xospata, Xtandi |
| Gilead Sciences, INC. | $865.00 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $822.42 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $809.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $720.11 | 2022-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Beigene USA, INC. | $607.32 | 2022-2025 | Brukinsa |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $589.32 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $565.47 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $526.16 | 2022-2023 | Lumakras, Kyprolis |
| Emd Serono, INC. | $462.96 | 2022-2025 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $432.77 | 2022-2025 | Opdivo |
| Abbvie INC. | $388.00 | 2022-2025 | Venclexta, Lupron Depot |
| Exelixis INC. | $355.17 | 2022-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.92 | 2022-2025 | Gilotrif |
| Genentech USA, INC. | $339.54 | 2022-2025 | Polivy, Phesgo, Venclexta |
| Stemline Therapeutics INC. | $324.70 | 2023-2025 | Orserdu |
| Seagen INC. | $283.88 | 2022-2023 | Tukysa |
| Eisai INC. | $254.87 | 2022-2025 | |
| Array Biopharma INC | $250.29 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $243.36 | 2022-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $238.98 | 2022-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $220.51 | 2024-2025 | Qinlock, Tgct |
| Pharmaessentia USA Corporation | $203.90 | 2022-2025 | Besremi |
| Blueprint Medicines Corporation | $191.35 | 2023-2025 | Ayvakit |
| Taiho Oncology, INC. | $125.07 | 2022-2024 | |
| G1 Therapeutics, INC. | $124.55 | 2022-2023 | Cosela |
| Secura Bio, INC. | $120.74 | 2024 | Copiktra |
| Coherus Oncology, INC. | $116.23 | 2024-2025 | Loqtorzi |
| Pharmacyclics LLC, An Abbvie Company | $108.05 | 2022-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $90.91 | 2024 | |
| Agios Pharmaceuticals, INC. | $84.10 | 2024-2025 | Pyrukynd |
| Novocure INC. | $80.93 | 2023-2025 | Optune, Optune Lua (Novottf-200t), Optune Gio |
| Sumitomo Pharma America, INC. | $80.53 | 2024 | Orgovyx |
| Jazz Pharmaceuticals INC. | $76.11 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $74.78 | 2023-2025 | Libtayo |
| Mirati Therapeutics, INC. | $74.51 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $74.35 | 2022-2025 | Tavalisse |
| Puma Biotechnology, INC. | $73.33 | 2022-2025 | |
| Ge Healthcare | $61.26 | 2025 | |
| Genmab U.S., INC. | $57.49 | 2023-2025 | Epkinly |
| Beone Medicines USA, INC. | $57.46 | 2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $54.45 | 2024-2025 | |
| Tolmar Pharmaceuticals, INC. | $52.80 | 2022 | |
| Accord Healthcare, INC. | $52.66 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $40.48 | 2022-2023 | Onivyde, Somatuline Depot |
| Recordati_rare_diseases_inc. | $35.17 | 2024-2025 | Enjaymo, Sylvant |
| Eusa Pharma (US) LLC | $34.84 | 2022 | |
| Morphosys, US INC. | $34.17 | 2023 | Monjuvi |
| Global Blood Therapeutics, INC. | $33.24 | 2022 | |
| Adc Therapeutics America, INC. | $29.88 | 2024 | |
| Sun Pharmaceutical Industries INC. | $28.16 | 2024 | |
| Iovance Biotherapeutics, INC. | $28.06 | 2025 | Amtagvi |
| Telix Pharmaceuticals | $27.59 | 2025 | Illuccix |
| Myovant Sciences INC. | $27.46 | 2022 | |
| Foundation Medicine, INC. | $25.48 | 2022 | |
| Tersera Therapeutics LLC | $24.79 | 2023 | Zoladex |
| Kite Pharma, INC. | $23.51 | 2023 | |
| Clovis Oncology, INC. | $23.42 | 2022 | |
| Sirtex Medical INC | $21.80 | 2022 | |
| Kyowa Kirin, INC. | $20.16 | 2024 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $18.02 | 2025 | |
| Syndax Pharmaceuticals, INC. | $17.72 | 2025 | |
| Tolmar, INC. | $16.52 | 2023 | |
| Menarini Silicon Biosystems, INC. | $16.36 | 2024 | |
| Immunogen, INC. | $15.74 | 2023 | Elahere |
| Macrogenics, INC. | $12.30 | 2022 | |
| Pharmaand Gmbh | $8.04 | 2025 | Rubraca |
Drugs and devices associated with these payments
Imfinzi $1,661Enhertu $1,373Keytruda $812Darzalex $707Vanflyta $650Doptelet $646Kisqali $637Imbruvica $616Lynparza $581Brukinsa $544Talvey $514Jemperli $504Jakafi $498Tecvayli $427Zejula $382Jaypirca $369Nubeqa $360Xtandi $337Vonjo $325Orserdu $325Cabometyx $304Verzenio $297Tukysa $285Monjuvi $269Vyloy $248Ibrance $243Talzenna $230Trodelvy $229Qinlock $221Erleada $215Orgovyx $214Braftovi $212Mektovi $206Gilotrif $202Ojjaara $198Venclexta $197Bavencio $193Balversa $192Tabrecta $192Ayvakit $191Bosulif $191Stivarga $189Calquence $185Xpovio $184Tagrisso $180Akeega $177Elrexfio $164Xospata $161Alunbrig $161Ninlaro $157Xofigo $150Polivy $149Scemblix $143Rybrevant $143Fruzaqla $138Lenvima $138Reblozyl $137Besponsa $136Besremi $135Welireg $131Ultomiris $129Copiktra $121Enjaymo $121Adcetris $119Epkinly $116Pemazyre $110Opdivo $108Lorbrena $108Phesgo $102Cosela $101Sarclisa $97.05Tibsovo $90.91Paxlovid $87.33Pyrukynd $84.10Xalkori $83.10Vitrakvi $83.00Pomalyst $81.45Lonsurf $76.21Inqovi $76.21Elahere $75.44Libtayo $74.78Krazati $74.51Udenyca $73.76Opdualag $65.80Synagis $63.05Illuccix $55.18Padcev $54.51Pylarify $54.45Camcevi $52.66Wayrilz $50.00Zepzelca $49.80Mekinist $44.90Lumakras $42.99Loqtorzi $42.47Inlyta $42.11Optune $39.96Tivdak $36.56Oxbryta $36.25Cablivi $33.89Comirnaty $30.59
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.